Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
| ▸ | NPY1R | P25929 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3688848 | 0.80 | MAPT (0.47) | KMT2AMEN1USP2KEAP1NFE2L2 | |
| SCHEMBL30197316 | 0.80 | ALDH1A1 (0.54) | PKMKMT2AMEN1NPY1RALDH1A1 | |
| SCHEMBL843559 | 0.80 | ALDH1A1 (0.54) | PKMKMT2AMEN1NPY1RALDH1A1 | |
| SCHEMBL8561095 | 0.78 | MEN1 (0.42) | KMT2AMEN1USP2KEAP1NFE2L2 | |
| Ammonia Solution, Strong SCHEMBL27851817 | 0.78 | ALDH1A1 (0.52) | PKMKMT2AMEN1NPY1RALDH1A1 | |
| SCHEMBL18486948 | 0.78 | KMT2A (0.42) | KMT2AMEN1USP2KEAP1NFE2L2 | |
| SCHEMBL18032590 | 0.77 | ALDH1A1 (0.41) | PKMKMT2AMEN1NPY1RALDH1A1 | |
| SCHEMBL4064206 | 0.77 | MEN1 (0.41) | KMT2AMEN1USP2KEAP1NFE2L2 | |
| SCHEMBL414810 | 0.77 | MEN1 (0.41) | KMT2AMEN1USP2KEAP1NFE2L2 | |
| SCHEMBL203785 | 0.77 | MEN1 (0.41) | KMT2AMEN1USP2KEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116410125-A | Preparation method of 2-methyl-3-nitro-4-hydroxypyridine | 嘉兴逸泰生物科技有限公司 | 2023-07-11 | — | — | CN | claimed |
| EP-3746441-A1 | PHARMACEUTICAL COMPOUND, SALTS THEREOF, FORMULATIONS THEREOF, AND METHODS OF MAKING AND USING SAME | GENENTECH, INC. (US) | 2020-12-09 | — | — | EP | claimed |
| WO-2019152863-A1 | PHARMACEUTICAL COMPOUND, SALTS THEREOF, FORMULATIONS THEREOF, AND METHODS OF MAKING AND USING SAME | GENENTECH, INC. (US) | 2019-08-08 | — | — | WO | claimed |
| WO-2025101780-A1 | PHARMACOLOGICAL CORRECTORS OF RHODOPSIN AND USES THEREOF | OCTANT, INC. (US) | 2025-05-15 | — | — | WO | disclosed |
| WO-2024215070-A1 | PYRAZOLOPYRIDINE DERIVATIVE COMPOUND, AND USE THEREOF | 보로노이 주식회사 | 2024-10-17 | — | — | WO | disclosed |
| CN-116410125-A | Preparation method of 2-methyl-3-nitro-4-hydroxypyridine | 嘉兴逸泰生物科技有限公司 | 2023-07-11 | — | — | CN | disclosed |
| CN-116410125-A | Preparation method of 2-methyl-3-nitro-4-hydroxypyridine | 嘉兴逸泰生物科技有限公司 | 2023-07-11 | — | — | CN | disclosed |
| US-20230192734-A1 | TRICYCLIC COMPOUNDS AS EGFR INHIBITORS | QILU PHARMACEUTICAL CO LTD (CN) | 2023-06-22 | — | — | US | disclosed |
| CN-114921468-A | Novel compound and method for producing regulatory T cell | 国立大学法人京都大学 | 2022-08-19 | — | — | CN | disclosed |
| CN-110234648-B | Novel compound and method for producing regulatory T cell | 国立大学法人京都大学 | 2022-06-14 | — | — | CN | disclosed |
| CN-105916503-B | Heteroaryl compounds and uses thereof | 米伦纽姆医药公司 | 2020-04-14 | — | — | CN | disclosed |
| WO-2015108861-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-07-23 | — | — | WO | disclosed |
| US-20080058383-A1 | Androgen Receptor Modulators | KARO BIO AB (SE) | 2008-03-06 | — | — | US | disclosed |
| EP-1685090-A1 | ANDROGEN RECEPTOR MODULATORS | KARO BIO AB (SE) | 2006-08-02 | — | — | EP | disclosed |
| WO-2005042464-A1 | ANDROGEN RECEPTOR MODULATORS | KARO BIO AB (SE) | 2005-05-12 | — | — | WO | disclosed |
| EP-0750620-A4 | CARBAPENEM COMPOUNDS, COMPOSITIONS AND METHODS OF TREATMENT | MERCK & CO INC (US) | 1997-07-16 | — | — | EP | disclosed |
| EP-0750620-A1 | CARBAPENEM COMPOUNDS, COMPOSITIONS AND METHODS OF TREATMENT | MERCK & CO. INC. (US) | 1997-01-02 | — | — | EP | disclosed |
| US-5496816-A | Carbapenem antibacterial compounds, compositions containing such compounds and methods of treatment | MERCK & CO., INC. (US) | 1996-03-05 | — | — | US | disclosed |
| WO-1995025108-A1 | CARBAPENEM COMPOUNDS, COMPOSITIONS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 1995-09-21 | — | — | WO | disclosed |
| US-5302601-A | Useful in the treatment of diseases mediated by platelet activating factor | G. D. SEARLE & CO. (US) | 1994-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192734-A1 | TRICYCLIC COMPOUNDS AS EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | PKM 2484/4885KMT2A 3421/4885MEN1 2200/4885 |
| US-20080058383-A1 | Androgen Receptor Modulators | NR5A1, ESRRA, AR | PKM 1525/4885KMT2A 3314/4885MEN1 1458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.